Replies to post #396047 on NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

Thanks for the reminder longfellow, it’s been a while since I’ve looked at that. The full question from my initial post was “We all know that the administration, source of antigen, (lysate vs. tumor tissue in vivo) activation method, and maturity of the cells are different, but what specifically in the cell characteristics and critical quality attributes of the actual dendritic cells are different?” So yes, I’m aware of many of the basic differences required for injection into a tumor’s hostile microenvironment vs. intradermal, as well as the delayed activation (method B) used in that -Direct trial. But that's a good point about the process being the product
So you think Dr. Bosch is the one to ask instead of ex? ;-)